" class="no-js "lang="en-US"> Shabbir Mostafa, Recipharm, on Medical Devices
Sunday, March 26, 2023

Breaking News

Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa Celyad Oncology Appoints Georges Rawadi as Its New CEO Companion Spine Closes $60.1 Million Series A Funding Round EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing Led by Gilde Healthcare Genprex CEO Commends FDA’s Initiative to Accelerate Approval Process for Gene Therapies OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases

February 22 2023

Shabbir Mostafa, Recipharm, on Medical Devices

In this video, Shabbir Mostafa, the Head of Business Development at Recipharm, discusses Recipharm’s focus on contract development and manufacturing of medical devices. He explains that Recipharm offers a wide range of services, from product development to manufacturing, packaging, and distribution.

Mostafa also highlights some of Recipharm’s recent projects, including the development of a nasal device for administering rescue medicines, as well as the production of innovative inhalers. He is passionate about showcasing Recipharm’s innovative products, as well as showing clients the company’s service from development, right through to commercialisation.

  1. Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa

    Diseases

     Read more
  2. Celyad Oncology Appoints Georges Rawadi as Its New CEO

    Appointments

     Read more
  3. Companion Spine Closes $60.1 Million Series A Funding Round

    Fundraising

     Read more
  4. EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis

    News

     Read more
  5. Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer

    Appointments

     Read more
More On